SEC Form 4 · accession 0001640455-19-000009
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Murray
Officer — CEO and President · Director
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 6:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 1, 2019 | A | 62,510 | $0.00 | A | 94,510 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.40 | Feb 1, 2019 | A | 125,010 | A | — | Feb 1, 2029 | Common Stock | 125,010 | 125,010 | D |
Explanation of responses
- F1The option will vest quarterly in 16 equal installments following January 1, 2019.